Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled study of ZHB107-108 sublingual tablets for house dust mite allergic rhinitis or rhinoconjunctivitis in adults
CTR20262902Phase 2Active
- Sponsor
- Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute
- Start
- Aug 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing ZHB107-108 sublingual tablet with ZHB107-108 placebo sublingual tablet (2 arms). Primary endpoint: Daily combined allergic rhinitis symptom and medication score. Started Aug 2026; status: active.
02
Drugs
ZHB107-108
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on CTR20262902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262902.